China's Venus Medtech jumps on completion of first-in-man clinical trial of product

Venus Medtech (Hangzhou)

23/12/2021 06:46

** Shares of Venus Medtech (Hangzhou) Inc  2500.HK  jump
7.9% to HK$27.95, on track for their biggest daily percentage
gain since Dec. 9
    ** Zhejiang, China-based co says https://bit.ly/3puGOO5 its
transcatheter aortic heart valve replacement system,
Venus-PowerX, had successfully completed its First-in-Man
clinical trial at West China Hospital of Sichuan University on
Dec. 21 
    ** The maker of medical devices for treatment of heart valve
diseases says it looks forward to the completion of the domestic
and international multi-centre clinical study of Venus-PowerX 
    ** The Hang Seng Commerce & Industry Index  .HSNC  gains
0.3% and the Hang Seng Composite Index on industrials  .HSCIIG 
rises 2.2%
    ** The healthcare index  .HSCIH  edges up 0.01% and the
benchmark Hang Seng Index  .HSI  gains 0.5%
    ** Stock had dropped 67.2% this year, as of last close

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))